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Hereditary cancers: clues to mechanisms of carcinogenesis
A.G. Knudson Jr
Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Summary The study of hereditary cancer in humans, notably retinoblastoma, has identified a category of
cancer genes that is different from that of the oncogenes. Whereas the latter group of genes exerts its effect
through expression, the former does so as a result of failure of normal expression. Primary oncogene
abnormality seems to play a crucial initiating role in certain neoplasms, particularly leukaemias, lymphomas
and some sarcomas. In contrast, anti-oncogenes (tumour suppressor genes) appear to be important in the
initiation of several solid tumours of children, as well as some common carcinomas of adults. Both classes are
apparently involved in tumour progression and metastasis.
Virtually every kind of cancer can occur in hereditary form, so the role of anti-oncogenes in the origin of
human cancers may be considerable. The prototypic anti-oncogene has been that for retinoblastoma. For this
tumour the recessive mechanism has been demonstrated by molecular means, and the gene has been cloned.
The possibility has been suggested that gene (or gene product) replacement therapy could be accomplished.
I am honoured to be invited to present the Ninth Gordon
Hamilton-Fairley Memorial Lecture of the British
Association for Cancer Research. Even though Professor
Hamilton-Fairley's career was tragically shortened, he will
long be remembered for his contributions to chemotherapy,
to cancer immunology and immunotherapy, and to the
development of medical oncology in all of its facets of
practice, research and training.
The problem of cancer, against which Professor Hamilton-
Fairley devoted so much of his intellect and energy, and to
which this meeting is addressed, continues to plague us.
Welcome as the advances in detection and treatment have
been, cancer remains a principal cause of mortality
throughout the world. Appreciation of this state of affairs
has continued to stimulate efforts to understand the biology
of cancer. A major theme of that topic, the role of the host
in tumour initiation and growth, embraces both the immune
response to cancer that intrigued Professor Hamilton-Fairley
and genetic predisposition to cancer, the subject of this
lecture.
Virtually every human cancer occurs in both normal and
genetically predisposed individuals. The most striking form
of genetic predisposition involves Mendelian dominant
inheritance with high penetrance, as shown for colon cancer
in persons with familial polyposis coli. In some instances, as
with polyposis, the carrier of the mutation is at high risk for
just one form of cancer. In others, as with familial non-
polyposis colon carcinoma, the carrier is at risk of several
different forms of cancer, although predisposition is never to
all forms. Tumour specificity is obviously quite variable. For
some cancers there is more than one hereditary
predisposition, as noted for colon carcinoma. We may
conclude that for nearly all cancers there is at least one
germline mutation that places its heterozygous carrier at
greatly increased risk of cancer.
Here I shall discuss selected hereditary cancers, the
relationship between the hereditary and non-hereditary forms
of the same cancer, and the class of gene they have revealed.
Retinoblastoma
A two-event modelfor the incidence of retinoblastoma
Retinoblastoma, an uncommon (approximately five cases per
100,000 births) tumour of children, has been a prototype in
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the study of hereditary cancer (Knudson, 1971, 1978). About
40% of cases are determined by a germline mutation, 60%
being non-hereditary. Most of the germline mutations are
new, with no family history of the tumour, but 50% of the
offspring of the germline cases are at risk of tumour,
whether the family history is positive or not. Virtually all
bilaterally affected persons seem to be germline cases, as are
10-15% of unilateral cases.
Since children with the germline mutation can have
bilateral or unilateral tumours, or even no tumours in rare
instances, the mutation is clearly not sufficient in
carcinogenesis. A second event was hypothesised as
necessary for tumour formation (Knudson, 1971). It was
posited that both events are also necessary for non-
hereditary cases, the difference being that the first event
occurs during early development rather than in a parental
germ cell. It was further proposed that in both hereditary
and non-hereditary cases the second event results in the loss
or mutation of both copies of a particular gene (Knudson,
1978). According to this hypothesis the retinoblastoma gene
is recessive in oncogenesis, at the cellular level, although
dominant with respect to imparting susceptibility to the
tumour.
Among gene carriers the tumours that develop were
counted and tested for a fit to the Poisson distribution, on
the thesis that some mean number of tumours is distributed
randomly as a result of a single somatic event. A good fit to
expectation was found for a mean of three tumours
(Knudson, 1971). Furthermore the bilateral cases not yet
diagnosed by a given age were plotted against age and found
to exhibit a linear decline on a semi-logarithmic plot, the
slope, -dlny/dt=k, being consistent with a single event. In
contrast, the unilateral (mostly non-hereditary) cases
followed a curvilinear distribution compatible with two
events.
Subsequently, Hethcote & Knudson (1978) developed a
mathematical model that related the incidence of
retinoblastoma, or any embryonal cancer, to cellular
processes. We assumed that in hereditary cases all cells in the
developing retina were at an intermediate, once-hit, stage,
and that a single mutation occurring at a rate p per cell
division would convert this target to a tumour cell. The
accumulated number of cell divisions was considered as a
function of time, a(t), such that it reached its final number
asymptotically during childhood. The mean number of
mutations, or tumours, m(t), at a particular time was
formulated as m(t) =/a(t), the final mean being
m(oo)=pa(oo). Since m(oo)=3, and since a(oo) is of the
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order of magnitude 107, p is of the order of magnitude of
10- 6. For non-hereditary cases another step, the somatic
conversion of normal target cells to mutant, once-hit,
intermediate cells was considered to occur at a rate v. The
target cells were in turn visualised as descendants of a few
committed precursor cells, whose small number was
designated b(o); this number is of the order of 10. The
number of tumours at time t, q(t), was formulated as
q(t) =pv{[a(t) +b(o)]{ln[a(t) +b(o)]-lnb(o)}-a(t)}. The final
incidence was approximated by the expression
q(oo)=pva(oo){ln[a(oo)/b(o)]-1}. With values of p and v of
the order of magnitude of 10-6 the value of q(oo) will be in
the range of 10-4 to 10-5, as observed. From these
equations the cases not yet diagnosed by a given age were
compared with observation and found to fit well for both
hereditary and non-hereditary cases.
Location and isolation of the retinoblastoma gene
A test of the two-event model for retinoblastoma depended
upon identifying the gene and looking for changes in both of
its copies. Chromosomal localisation was possible because a
small percentage of cases have constitutional deletions that
include chromosomal band 13q14 (Knudson et al., 1976;
Francke & Kung, 1976; Yunis & Ramsay, 1978). These
deletions include loss of an adjacent gene, that for esterase D
(Sparkes et al., 1980), which was then used as a marker in
linkage studies for the inheritance of the non-deletion form.
No recombinants were found, indicating close linkage
(Sparkes et al., 1983).
It was predicted that the second event entailed loss or
mutation in the same gene in the homologous chromosome
by one of four mechanisms: local mutation, chromosomal
deletion, non-disjunction and resultant monosomy 13, or
somatic recombination (Knudson, 1978). The esterase D gene
was used by two groups of investigators to study this
problem (Godbout et al., 1983; Benedict et al., 1983). In one
study it was found, in some patients who were heterozygous
at the esterase D locus, that the tumour was hemizygous or
homozygous, suggesting deletion, monosomy or
*rgcombination (Godbout et al., 1983). In the other study a
patient had a constitutional level of esterase D only 50% of
normal, suggesting an occult chromosomal deletion (Benedict
et al., 1983). The tumour contained only one chromosome 13
and no esterase D, indicating loss of the normal
chromosome 13.
A more general method for the study of the second event
was introduced by Cavenee et al. (1983). This involves the
use of DNA probes that detect common polymorphic
segments of restriction enzyme-digested DNA. Such
restriction fragment length polymorphisms (RFLPs) were
used to show that non-local events occur in at least 50% of
retinoblastomas, i.e. in these cases the heterozygosity that
was observed in blood cells was not present in tumour cells.
The clear demonstration of somatic recombination in one
tumour was the first demonstration of that phenomenon in
humans.
Such linked markers were then used to search for the
retinoblastoma gene and for abnormalities in retinoblastoma.
One such marker was localised to the immediate region and
found to be abnormal in a few tumours (Dryja et al., 1986).
Using this probe, Friend et al. (1986) were able to clone the
retinoblastoma gene and to discover abnormality of structure
or function in many cases of the tumour. This fraction of
abnormalities will undoubtedly increase as more detailed
studies of the gene are performed. This discovery has been
verified and extended by these and other investigators
(Bookstein et al., 1988; Dunn et al., 1988; Friend et al.,
1987; Fung et al., 1987; Lee et al., 1987a, b).
Other tumours of children
Osteosarcoma
Some patients with retinoblastoma subsequently develop
second cancers at other sites, chief among these being
osteosarcoma. These second tumours occur predominantly in
bilaterally affected individuals, indicating that it is only the
heritable cases that have this predisposition. It would seem
that the retinoblastoma gene is also an osteosarcoma gene.
The retinoblastoma gene probes were used to test this idea in
non-hereditary cases of osteosarcoma. Indeed, abnormalities
of the locus have been found in a significant fraction of
cases by several groups of investigators (Friend et al., 1986,
1987; Fung et al., 1987; Lee et al., 1987a; Weichselbaum et
al., 1988). Whether osteosarcoma involves only this locus has
not been ascertained.
Wilms' tumour and rhabdomyosarcoma
Since Wilms' tumour demonstrated some of the features
found for retinoblastoma, it was also predicted to be caused
by two events, the events being at the same loci in both the
hereditary and non-hereditary forms (Knudson & Strong,
1972). A small fraction of cases is associated with congenital
aniridia (Miller et al., 1964), an association that was
attributed to heterozygous deletion of both loci (Knudson &
Strong, 1972). Such deletions were subsequently found and
localised to chromosomal band 13q14 (Francke et al., 1979).
The use of syntenic RFLPs permitted demonstration of loss
of heterozygosity in a majority of cases, supporting the idea
that the second event affected the homologous locus (Fearon
et al., 1984; Koufos et al., 1984; Orkin et al., 1984; Reeve et
al., 1984).
What is lacking in the Wilms' tumour story is evidence of
linkage of the inherited mutation to markers on
chromosome lp, as was demonstrated for retinoblastoma
with esterase D. Another problem arises in connection with
the Beckwith-Wiedemann syndrome, which is a rare
dominantly heritable condition that predisposes to Wilms'
tumour, as well as to hepatoblastoma, adrenocortical
carcinoma and rhabdomyosarcoma. This predisposition is
very different from that of hereditary Wilms' tumour, which
does not predispose to these other tumours and which does
not display the phenotypic features of the Beckwith-
Wiedemann syndrome. Some cases of the latter have been
associated with partial trisomy of chromosome band 1lplS
(Turleau et al., 1984; Waziri et al., 1983). Examination of
non-hereditary rhabdomyosarcomas has revealed consistent
loss of heterozygosity for Ilp markers, frequently by
recombination (Scrable et al., 1987). When enough markers
were present, the loss was found to involve certain distal
markers but not one or more located between llpl3 and
llp15, suggesting deletion or recombination with a break-
point between the two bands.
Another syndrome complicates the picture still further.
This is the syndrome of breast cancer in association with
other tumours: soft tissue sarcoma, osteosarcoma, glioma,
leukaemia and adrenocortical carcinoma (Li & Fraumeni,
1975). One of the soft tissue sarcomas is embryonal
rhabdomyosarcoma, the very tumour that often shows loss
of heterozygosity for lIlp5 markers, while two others,
osteosarcoma and some cases of breast cancer, show
abnormality of the retinoblastoma gene on chromosome 13q.
How then can one gene predispose to tumours associated
with what may be primary events occurring at two different
chromosomal sites? One possibility is that dominant
inheritance in this case has a different meaning. Is it possible
that a mutant oncogene is involved, with an effect on
numerous tissues, and that the recessive genes in these tissues
must still be mutated in order to produce tumour. Perhaps a
precedent for such an idea is the syndrome, multiple
endocrine neoplasia type II, which has been found to be
linked to chromosome 10 (Mathew et al., 1987a; Simpson et
al., 1987). In this syndrome there is loss of heterozygosity for
markers on chromosome lp, but not for markers on
chromosome 10 (Mathew et al., 1987b).HEREDITARY CANCERS 663
Tumours of adults
A two-step model for the incidence of adult cancers
It is well known that the age-specific incidences of most
cancers of adults increase steeply with age. For many cancers
this relationship is approximated by the equation I=kt,
where r is a constant. If mutation plays a determining role in
carcinogenesis, one could explain the relationship by
supposing an age-dependent increase in mutation rate.
However, there is considerable evidence against this idea.
Another explanation is that a target cell must sustain more
than one mutation. Various authors, notably Armitage &
Doll (1954), have proposed that (r+ 1) mutations, occurring
at constant rates with age, could account for the
relationship; thus, for many cancers, r=6, so seven events
were proposed. Objections to this model include a
requirement for very high rates of somatic mutation and
neglect of the fact that the tissues that give rise to these
tumours are renewal tissues, i.e. the cells are
undergoing birth and death processes. Moolgavkar
and his colleagues (Moolgavkar & Knudson, 1981;
Moolgavkar & Venzon, 1979) have taken these processes
into account, and shown that the observed incidences can be
fitted by a model that requires only two rate-limiting events,
as required by the recessive cancer gene formulation. Indeed,
the incidences of the tumours of children can also be fitted to
this model, by taking into account the formation and
differentiation of the embryonic precursor cells in the target
tissues. The variables of the model include a time-dependent
function, X(s), that describes the population of target cells.
For a tissue such as retina, the target cells (retinoblasts)
appear in the embryo, grow to large numbers and differen-
tiate. The disappearance of these cells accounts for the
absence of tumours beyond childhood. The two somatic
mutations are regarded as occurring at constant rates of p1
and p2. Cells that have sustained just one mutation undergo
mitosis at a rate a, and differentiation at a rate 1,. so that
their net growth is described as a function of (cxa-f). The
age-specific incidence, I(t), at time t, becomes therefore:
I(t) =P1P2 J X(s) exp[(ax-f)(t-s)] ds.
0
This model has been fitted to data on cancers of breast,
colon and lung.
A two-event model accommodates the notion of recessive
cancer genes that are critical in carcinogenesis. It also
identifies the kinetics of target cells and once-hit cells as
important parameters upon which such agents as tumour
promoters could have a profound effect. The model does not
impose a limitation upon the number of events that a cancer
cell may have sustained. Thus, further mutations that
improve the cell's growth advantage are not incompatible.
The model does state that only two events are rate-limiting,
i.e. necessary for establishment of a cancer. One can
therefore inquire whether just two events, such as loss or
mutation of two copies of a particular gene, may be
operative in the common cancers of adults.
Meningioma and acoustic neuroma
Although not common, two tumours that occur primarily in
adults, meningioma and acoustic neuroma, do seem to fit the
two-event model of a recessive cancer gene. In both of these
tumours deletion or monosomy of chromosome 22 is
common, as is loss of heterozygosity for syntenic markers
(Meese et al., 1987; Seizinger et al., 1986, 1987).
Furthermore, a hereditary condition, central neuro-
fibromatosis, that predisposes to acoustic neuroma and
meningioma is attributable to mutation of a gene mapped by
linkage studies to chromosome 22 (Rouleau et al., 1987).
One patient who died with multiple meningiomas had a
constitutional abnormality of chromosome 22 (Arinami et
al., 1986). Whether a single gene on this chromosome is
responsible for both tumours is not known. Although no
gene has yet been cloned that satisfies the criteria for a
recessive cancer gene on this chromosome, there is a strong
presumption that for these tumours two events are necessary,
they involve the two copies of a gene on chromosome 22,
and inheritance of a mutation of one copy predisposes
strongly to tumour formation. There is no evidence that
other genetic changes are necessary.
Carcinoma of the kidney
Genetic predisposition to renal carcinoma has been reported
numerous times, but in one family there was a cytogenetic
clue to the location of the responsible mutant gene (Cohen et
al., 1979). This clue was a reciprocal translocation between
chromosomes 3 and 8, the breakpoint in chromosome 3 being
at 3p14 (Wang & Perkins, 1984). This finding stimulated the
investigation of renal carcinoma generally, with the resultant
discovery that deletion and/or loss of heterozygosity for
syntenic markers of 3p is very common (Kovacs et al., 1988;
Zbar et al., 1987), although there is still no evidence that the
tumours contain no normal copies of a particular gene. In
families with renal carcinoma the penetrance of the gene is
very high, and other tumours are not reported in excess, so
the gene would seem to be highly tissue-specific in
oncogenesis. There is a dominantly heritable syndrome, von
Hippel-Lindau, that predisposes to renal carcinoma, often
bilateral, whose responsible gene has been mapped to
chromosome 3p (Seizinger et al., 1988). Is this gene separate
from, or identical to, the mutation that produces only
predisposition to renal carcinoma? One possibility is that the
syndrome involves a submicroscopic deletion that includes
the renal carcinoma gene and another gene that accounts for
the other features of the syndrome.
Carcinoma of the colon
Hereditary predisposition to colon cancer is known in two
forms, with and without polyposis. Familial polyposis coli
has a world-wide incidence of the order of magnitude of one
per 10,000 births, being sustained at this frequency by a
balance between new germline mutations and deaths before
the end of the reproductive period, according to the equation
heterozygote frequency =2p/s, where p is the germinal
mutation rate, and s is the coefficient of selection, such that
the relative fitness of a carrier is 1-s. Cancer in polyposis
coli patients is largely limited to the colon, although patients
with the clinical variant known as Gardner's syndrome may
develop fibrosarcoma.
Familial non-polyposis colon cancer is a less sharply
defined syndrome in that predisposition regularly extends to
other cancers, especially endometrial carcinoma. Its
frequency is not precisely known, although some
investigators believe that it is more frequent than polyposis
coli. The penetrance of the mutant gene for colon cancer is
very high and for some cancer virtually 100%. It is
interesting that the colon cancers seen in this condition more
often occur in the proximal than in the distal colon, contrary
to the distribution noted in polyposis coli.
The two-event model has been applied to colon cancer,
with the proposal that the non-hereditary form should in
some cases involve somatic mutations at the two copies of
the familial polyposis coli gene, and in others, at the two
copies of the gene for non-polyposis cancer (Knudson, 1985).
This is a minimal model, since there may be still other genes
that predispose to colon cancer. The relative frequency of
the two kinds of mutations in non-hereditary colon cancer
might be expected to favour the polyposis coli gene, because
colon cancer generally involves the distal rather than the
proximal colon.
The chromosomal location of the polyposis coli gene has
permitted a partial test of the hypothesis. One patient with
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constitutional deletion of chromosome arm 5q (Herrera et
al., 1986). Utilising syntenic polymorphic DNA markers, two
groups of investigators were able to demonstrate linkage of
the polyposis coli gene to this chromosome arm (Bodmer et
al., 1987; Leppert et al., 1987). The presumption would then
be that some fraction of non-hereditary colon cancers should
show loss of heterozygosity for syntenic markers, the idea
being that a somatic mutation had occurred at one copy of
the gene, and a gross chromosomal event such as deletion,
chromosomal loss or recombination had led to loss of the
other normal copy. Solomon et al. (1987) reported such loss
at a frequency of 23%, or perhaps higher. Other investi-
gators have since reported frequencies in the range of 19-
36% (Law et al., 1988; Vogelstein et al., 1988). If gross
second events and local second events (not associated with
loss of heterozygosity for syntenic markers) occur at approx-
imately equal frequencies in colon cancer, then one might
conclude that the polyposis coli gene is a critical determinant
in approximately 50% of cases. There are only a few reports
of studies of tumours in polyposis coli patients, so the
fraction showing loss of heterozygosity is not known; this
could be a guide to conclusions about the non-hereditary
cases.
There is no information about the location of the non-
polyposis colon cancer, but one may begin by assuming that
it is not on Sq. Too few tumours from such patients have
been analysed to know if this is true. Another approach to
the problem has been taken through the study of expression
of the c-myc oncogene in colon cancer. Approximately 70%
of colon cancers show significantly elevated expression of c-
myc (Erisman et al., 1985). However, a high fraction of
tumours in the proximal colon did not show elevated
expression of c-myc, suggesting the possibility that tumours
arising as a result of mutation at the polyposis coli locus,
whether germinal or somatic, show elevated expression, while
those arising at the non-polyposis locus do not. In such a
case tumours expressing elevated c-myc levels should show
about 50% or so loss of heterozygosity for 5q markers, and
those without elevation should not show such loss.
Some investigators have found loss of heterozygosity for
markers other than those on 5q, particularly for 17p and 18q
(Law et al., 1988; Vogelstein et al., 1988). Oncogenic muta-
tions have also been found in K-ras and N-ras. All of these
changes are thought to have arisen after the tumours began
and to represent steps in progression. They can be viewed as
providing growth advantage to a tumour, but not as produc-
ing the original transformation of the tumour, which seems
to be the case for the mutations at the polyposis coli locus.
These studies of colon cancer suggest the possibility that
recessive genes may be operative at more than one stage in
the birth and evolution of tumours.
Other cancers
Carcinoma of the breast is also known to exist in two
hereditary forms, one not in association with other tumours
(perhaps ovarian cancer is an exception), and one associated
with numerous other tumours in the patients or other
members of the family. The principal other tumours are soft
tissue sarcoma, osteosarcoma, glioma, leukaemia, and
adrenocortical carcinoma, as noted previously. So far there
has been no localisation of either gene. Some clues come
from the study of tumours with polymorphic DNA probes.
Loss of heterozygosity has been reported for 13q markers in
four of ten cases of ductal carcinoma, and for Ilp markers
in 20% of stage II and III breast carcinomas (Ali et al.,
1987; Lundberg et al., 1987). Abnormality of the retinoblas-
toma locus has been reported in two of nine tumour cell
lines (Lee et al., 1988). It will be of great interest to know
whether the gene for the syndrome of breast cancer with
other tumours is identical with, or linked to, the retinoblas-
toma gene. Identity of the predisposing genes seems unlikely
in view of the very high penetrance of the breast cancer-
sarcoma syndrome for breast cancer along with the lack of
such penetrance in hereditary retinoblastoma cases, and the
absence of retinoblastoma itself in the breast cancer syn-
drome, even though hereditary retinoblastoma shows extre-
mely high penetrance. Another possibility is that the
retinoblastoma locus is sometimes involved in tumour
progression.
Recessive mechanisms have also been invoked for small
cell carcinoma of the lung. Deletions of chromosome 3p have
been found frequently in this tumour, as has loss of hetero-
zygosity for syntenic 3p markers (Kok et al., 1987; Naylor et
al., 1987; Yokota et al., 1987). The suspected gene has not
yet been cloned. In addition some of the small cell carci-
noma lines that were examined in one study showed abnor-
mality of the retinoblastoma gene (Harbour et al., 1988).
Here again questions arise regarding the stage in the deve-
lopment of these cancers when the genetic changes occur.
Discussion
Two classes of genes have been implicated in the origin of
human cancer: oncogenes and anti-oncogenes (or tumour
suppressor genes). The strongest evidence for a primary role
of the former comes from certain leukaemias, lymphomas
and sarcomas in which specific translocations are found. The
latter class of cancer gene has been implicated in the origin
of certain paediatric tumours and in several common carci-
nomas. Although abnormal structure or expression of both
classes can apparently occur during tumour progression,
primary anti-oncogene abnormality appears to involve a
broader spectrum of tumours than does oncogene abnor-
mality. This impression is fortified by studies of somatic cell
hybrids between tumorous and normal cells in which tumori-
genicity is usually suppressed.
The list of anti-oncogenes will undoubtedly grow, since
there are at least 50 dominantly heritable conditions that
predispose to cancer and many of them probably involve this
mechanism. The common carcinomas will almost certainly
demonstrate heterogeneity of genetic mechanism, because at
least two different hereditary states predispose to them, as in
colon cancer and breast cancer. This diversity of genes
undoubtedly plays a role in normal histogenesis. For exam-
ple, a series of genes is associated with oncogenesis in neural
crest derivatives; different genes predispose to neuroblas-
toma, pheochromocytoma, melanoma, carotid body
tumours, medullary carcinoma of the thyroid and neuro-
fibrosarcoma.
A provocative question that arises in a consideration of
anti-oncogenes is 'can these genes or their products be
turned to therapeutic use?' If tumour formation results from
loss of function, will tumour reversion result from resto-
ration of function? The suppression of tumorigenicity in
somatic cell hybrids suggests that such a goal might be
achieved. Indeed, Weissman et al. (1987) have demonstrated
loss of tumorigenicity of Wilms' tumour cells following
fusion with a normal chromosome arm llp. Furthermore,
Huang et al. (1988) have achieved in vitro reversion of
retinoblastoma cells by retrovirally mediated transfer of
retinoblastoma gene cDNA. Whether this approach could
succeed in vivo is obviously a question of great importance.
Another approach might involve supplying the protein pro-
duct of the gene. In either case an entirely new approach to
the treatment of cancer has been conceived.
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